Society ❯ Health Issues ❯ Obesity

Treatment Options

Patient Experiences Patient Access GLP-1 Drugs Lifestyle Medications Economic Impact Wegovy Injections for Weight Loss Pharmaceutical Innovations Access to Medications Medication Access Public Perception

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

The upgrade positions the site to supply markets outside the U.S. ahead of a possible EMA decision on the Wegovy pill.

Eli Lilly Unveils $3 Billion Netherlands Plant to Scale Production of Oral Weight‑Loss Pill